- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05193279
Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age
March 22, 2023 updated by: Clover Biopharmaceuticals AUS Pty Ltd
A Randomized, Controlled, Dose-finding, Observer-blind, Phase 2/3 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of CpG/Alum-adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccines (SCB-2019 Vaccine) in Children <18 Years of Age
This is a phase 2/3, randomized, controlled study to assess the reactogenicity, safety and immunogenicity of adjuvanted recombinant SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019), when administered as 2-dose vaccination series in children below 18 years of age.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Margaret Khin, MD
- Email: Margaret.Khin@cloverbiopharma.com
Study Locations
-
-
-
Barranquilla, Colombia, 080020
- Clinica de la Costa Ltda
-
Contact:
- Maria Alexandra Castañeda, M.Sc
- Phone Number: +5753736200
- Email: lbrochado@clinicadelacosta.co
-
Contact:
- Daniela Higgins Molina, Physician
-
Principal Investigator:
- Dr. Leonardo Fabio Brochado Fontalvo, M.D.
-
Cali, Colombia
- Centro de Estudios en Infectología Pediátrica S.A.S. - CEIP S.A.S.
-
Contact:
- Hilda Giraldo Orjuela
- Phone Number: +5724860220X1113
- Email: pio.lopez@ceiponline.org
-
Contact:
- Julio Cesar Rengifo
-
Principal Investigator:
- Dr. Pio Lopez, M.D
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 17 years (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female <18 years of age. Participants will be stratified into different age cohorts (≥12 to < 18 years, ≥5 to < 12 years, ≥2 to < 5 years, and < 2 years of age) based on the age on the day of inclusion.
- Individuals and their legally authorized representative (LAR) are willing and able to comply with study requirements, including all scheduled visits, vaccinations, laboratory tests and other study procedures.
- Individuals are willing and able to give an assent (if applicable) and their LARs are willing and able to give informed consent on their behalf, prior to screening
- Healthy participants (phase 2 and phase 3) or participants with pre-existing medical conditions who are in a stable medical condition (phase 2)
- For infants (<1-year-old) - born at full term (gestational age ≥37 weeks) and with a normal birth weight (≥2500 grams).
- Female participants of childbearing potential may be enrolled in the study, if the participant has practiced highly effective contraception for 30 days prior to vaccination, and has a negative pregnancy test on the day of vaccination and has agreed to continue adequate contraception for 3 months after the last vaccination
Exclusion Criteria:
- Individuals with fever >38.0°C [≥ 100.4°F] (irrespective of method used), or any acute illness at baseline (Day 1) or within 3 days prior to randomization.
- Individuals with laboratory-confirmed SARS-CoV-2 infection [as defined by Rapid COVID Antigen Test or an equivalent at Day 1] or with history of laboratory-confirmed/medically-diagnosed COVID-19 (for phase 2 participants only).
- Individuals who have received an investigational or licensed COVID-19 vaccine prior to Day 1, or plan to receive an investigational or licensed COVID-19 vaccine during the study period.
- Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease [e.g., malignancy, human immunodeficiency virus (HIV) infection] or immunosuppressive/cytotoxic therapy (e.g., systemic corticosteroids, medications used for cancer chemotherapy, organ transplantation or to treat autoimmune disorders) within 3 months prior to Day 1. Inhaled, intranasal, topical steroids as well as a single dose of systemic steroids, are allowed.
- Individuals with any progressive or severe neurologic disorder, seizure disorder (including febrile seizures) or history of Guillain-Barré syndrome.
- Individuals who are pregnant, or breastfeeding, or planning to become pregnant while enrolled in this study or during the study period.
- Individuals who have a history of severe adverse reaction associated with a vaccine or severe allergic reaction
- Individuals who have received any other investigational product within 30 days prior to Day 1 or intend to participate in another clinical study at any time during the conduct of this study.
- Individuals who have received any other licensed vaccines within 14 days prior to enrollment in this study or who are planning to receive any vaccine up to 28 days after the second (phase 2) or third (phase 3) vaccination.
- Individuals with known bleeding disorder that would, in the opinion of the investigator, contraindicate intramuscular injection
- Administration of intravenous immunoglobulins and/or any blood products within 3 months prior to enrollment or planned administration during the study period
- Individuals with any condition that, in the opinion of the investigator, would interfere with the primary study objectives or pose additional risk to the participant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SCB-2019/SCB-2019/placebo, 12 to < 18 yrs
Day 1 and 22: SCB-2019, Day 43: placebo
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: Placebo/SCB-2019/SCB-2019, 12 to < 18 years
Day 1: placebo, Day 22 and 43: SCB-2019
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: SCB-2019/placebo/SCB-2019, 12 to < 18 years
Day 1 and 43: SCB-2019, Day 22: placebo
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: Low dose SCB-2019, 5 to < 12 years
Day 1 and 22: SCB-2019
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: Mid dose SCB-2019, 5 to < 12 years
Day 1 and 22: SCB-2019
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: High dose SCB-2019, 5 to < 12 years
Day 1 and 22: SCB-2019
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: SCB-2019/SCB-2019/placebo, 5 to < 12 yrs
Day 1 and 22: SCB-2019, Day 43: placebo
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: Placebo/SCB-2019/SCB-2019, 5 to < 12 years
Day 1: placebo, Day 22 and 43: SCB-2019
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: SCB-2019/placebo/SCB-2019, 5 to < 12 years
Day 1 and 43: SCB-2019, Day 22: placebo
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: Low dose SCB-2019, 2 to < 5 years
Day 1 and 22: SCB-2019
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: Mid dose SCB-2019, 2 to < 5 years
Day 1 and 22: SCB-2019
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: High dose SCB-2019, 2 to < 5 years
Day 1 and 22: SCB-2019
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: SCB-2019/SCB-2019/placebo, 2 to < 5 yrs
Day 1 and 22: SCB-2019, Day 43: placebo
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: Placebo/SCB-2019/SCB-2019, 2 to < 5 years
Day 1: placebo, Day 22 and 43: SCB-2019
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: SCB-2019/placebo/SCB-2019, 2 to < 5 years
Day 1 and 43: SCB-2019, Day 22: placebo
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: Low dose SCB-2019, birth to < 2 years
Day 1 and 22: SCB-2019
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: Mid dose SCB-2019, birth to < 2 years
Day 1 and 22: SCB-2019
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: High dose SCB-2019, birth to < 2 years
Day 1 and 22: SCB-2019
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: SCB-2019/SCB-2019/placebo, birth to < 2 yrs
Day 1 and 22: SCB-2019, Day 43: placebo
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: Placebo/SCB-2019/SCB-2019, birth to < 2 years
Day 1: placebo, Day 22 and 43: SCB-2019
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
Experimental: SCB-2019/placebo/SCB-2019, birth to < 2 years
Day 1 and 43: SCB-2019, Day 22: placebo
|
a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 2, select optimal dose level of SCB-2019 vaccine by age cohort (5-11 years, 2-4 years, and < 2 years), based on safety
Time Frame: 7 days after dose 1 (Day 1-7)
|
Proportion of subjects with solicited local and systemic adverse events
|
7 days after dose 1 (Day 1-7)
|
Phase 2, select optimal dose level of SCB-2019 vaccine by age cohort (5-11 years, 2-4 years, and < 2 years), based on safety
Time Frame: 7 days after dose 2 (Day 22-28)
|
Proportion of subjects with solicited local and systemic adverse events
|
7 days after dose 2 (Day 22-28)
|
Phase 2, select optimal dose level of SCB-2019 vaccine in phase 2 by age cohort (5-11 years, 2-4 years, and < 2 years), based on immunogenicity
Time Frame: Day 36
|
Geometric mean titer (GMT) of SARS-CoV-2 neutralising antibody (nAb)
|
Day 36
|
Phase 3, non-inferiority (GMT) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants 5 to < 12 years as compared to young adults (18 to < 25 years)
Time Frame: 21/15 days after second SCB-2019 dose
|
GMT of SARS-CoV-2 nAb after 2 doses of SCB-2019 vaccine in participants 5 to 12 years over GMT in participants 18 to < 25 years from CLO-SCB-2019-003 study
|
21/15 days after second SCB-2019 dose
|
Phase 3, non-inferiority (GMT) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants 2 to < 5 years as compared to young adults (18 to < 25 years)
Time Frame: 21/15 days after second SCB-2019 dose
|
GMT of SARS-CoV-2 nAb after 2 doses of SCB-2019 vaccine in participants 2 to 5 years over GMT in participants 18 to < 25 years from CLO-SCB-2019-003 study
|
21/15 days after second SCB-2019 dose
|
Phase 3, non-inferiority (GMT) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants birth to < 2 years as compared to young adults (18 to < 25 years)
Time Frame: 21/15 days after second SCB-2019 dose
|
GMT of SARS-CoV-2 nAb after 2 doses of SCB-2019 vaccine in participants birth to 2 years over GMT in participants 18 to < 25 years from CLO-SCB-2019-003 study
|
21/15 days after second SCB-2019 dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase 3, non-inferiority (SCR difference) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants 5 to < 12 years as compared to young adults (18 to < 25 years)
Time Frame: 21/15 days after second SCB-2019 dose
|
Proportion of participants achieving seroconversion for SARS-CoV-2 nAb after 2 doses of SCB-2019 vaccine in participants 5 to < 12 years minus proportion in participants 18 to < 25 years from CLO-SCB-2019-003 study
|
21/15 days after second SCB-2019 dose
|
Phase 3, non-inferiority (SCR difference) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants 2 to < 5 years as compared to young adults (18 to < 25 years)
Time Frame: 21/15 days after second SCB-2019 dose
|
Proportion of participants achieving seroconversion for SARS-CoV-2 nAb after 2 doses of SCB-2019 vaccine in participants 2 to < 5 years minus proportion in participants 18 to < 25 years from CLO-SCB-2019-003 study
|
21/15 days after second SCB-2019 dose
|
Phase 3, non-inferiority (SCR difference) of SARS-CoV-2 nAb titers of SCB-2019 vaccine when given to participants birth to < 2 years as compared to young adults (18 to < 25 years)
Time Frame: 21/15 days after second SCB-2019 dose
|
Proportion of participants achieving seroconversion for SARS-CoV-2 nAb after 2 doses of SCB-2019 vaccine in participants birth to < 2 years minus proportion in participants 18 to < 25 years from CLO-SCB-2019-003 study
|
21/15 days after second SCB-2019 dose
|
In phase 2 and 3, GMT of SARS-CoV-2 nAb
Time Frame: Day 1 , 22 and 36 (phase 2) and Day 1, 43, 64, 226 and 410 (phase 3)
|
Day 1 , 22 and 36 (phase 2) and Day 1, 43, 64, 226 and 410 (phase 3)
|
|
In phase 2 and 3, proportion of participants achieving seroconversion for SARS-CoV-2 nAb
Time Frame: Day 22 and 36 (phase 2) and Day 43, 64, 226 and 410 (phase 3)
|
Day 22 and 36 (phase 2) and Day 43, 64, 226 and 410 (phase 3)
|
|
In phase 2 and 3, GMFR in SARS-CoV-2 nAb
Time Frame: Day 22 and 36 (phase 2) and Day 43, 64, 226 and 410 (phase 3)
|
Day 22 and 36 (phase 2) and Day 43, 64, 226 and 410 (phase 3)
|
|
In phase 2 and 3, proportion of participants with SARS-CoV-2 nAb above a certain threshold
Time Frame: Day 1 , 22 and 36 (phase 2) and Day 1, 43, 64, 226 and 410 (phase 3)
|
Day 1 , 22 and 36 (phase 2) and Day 1, 43, 64, 226 and 410 (phase 3)
|
|
In phase 2 and 3, GMT of SCB-2019 Binding Antibody
Time Frame: Day 1 , 22 and 36 (phase 2) and Day 1, 43, 64, 226 and 410 (phase 3)
|
Day 1 , 22 and 36 (phase 2) and Day 1, 43, 64, 226 and 410 (phase 3)
|
|
In phase 2 and 3, proportion of participants achieving seroconversion for SCB-2019 binding antibody
Time Frame: Day 22 and 36 (phase 2) and Day 43, 64, 226 and 410 (phase 3)
|
Day 22 and 36 (phase 2) and Day 43, 64, 226 and 410 (phase 3)
|
|
In phase 2 and 3, GMFR of SCB-2019 binding antibody
Time Frame: Day 22 and 36 (phase 2) and Day 43, 64, 226 and 410 (phase 3)
|
Day 22 and 36 (phase 2) and Day 43, 64, 226 and 410 (phase 3)
|
|
In phase 2 and 3, proportion of participants with SCB-2019 binding antibody above a certain threshold
Time Frame: Day 1 , 22 and 36 (phase 2) and Day 1, 43, 64, 226 and 410 (phase 3)
|
Day 1 , 22 and 36 (phase 2) and Day 1, 43, 64, 226 and 410 (phase 3)
|
|
In phase 3, reactogenicity of the vaccine as indicated by the occurrence of solicited local and systemic reactions
Time Frame: 7 days after dose 1 (Day 1-7), dose 2 (Day 22-Day 28) and Dose 3 (Day 43-49)
|
In phase 3, proportion of participants with local and systemic AEs
|
7 days after dose 1 (Day 1-7), dose 2 (Day 22-Day 28) and Dose 3 (Day 43-49)
|
Phase 2 and 3, safety of the vaccine in terms of occurrence of unsolicited adverse events
Time Frame: Up to 21 days after the last vaccination
|
Proportion of subjects with unsolicited adverse events
|
Up to 21 days after the last vaccination
|
Phase 2 and 3, safety of the vaccine in terms of occurrence of MAAEs, SAEs, adverse events leading to discontinuation from study, and AESIs.
Time Frame: During the entire study period
|
Proportion of participants with any adverse events in this category.
|
During the entire study period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 5, 2022
Primary Completion (Actual)
December 15, 2022
Study Completion (Actual)
December 15, 2022
Study Registration Dates
First Submitted
December 23, 2021
First Submitted That Met QC Criteria
January 11, 2022
First Posted (Actual)
January 14, 2022
Study Record Updates
Last Update Posted (Actual)
March 24, 2023
Last Update Submitted That Met QC Criteria
March 22, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- CLO-SCB-2019-007
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Candidate vaccine, SCB-2019
-
Zhejiang Clover Biopharmaceuticals, Inc.Active, not recruiting
-
Clover Biopharmaceuticals AUS Pty LtdCompleted
-
Clover Biopharmaceuticals AUS Pty LtdInternational Vaccine Institute; Coalition for Epidemic Preparedness InnovationsCompletedCOVID-19Colombia, Belgium, Brazil, Philippines, South Africa
-
Clover Biopharmaceuticals AUS Pty LtdCompletedCOVID-19South Africa
-
Clover Biopharmaceuticals AUS Pty LtdRecruitingRespiratory Syncytial Virus InfectionAustralia
-
Clover Biopharmaceuticals AUS Pty LtdWithdrawn
-
Clover Biopharmaceuticals AUS Pty LtdCompleted
-
D'Or Institute for Research and EducationBill and Melinda Gates FoundationActive, not recruiting
-
Anderson Clinical ResearchLigand PharmaceuticalsCompletedHIV Infections | Sarcoma, Kaposi